Comparative Pharmacology
Head-to-head clinical analysis: LIVALO versus PRAVACHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVALO versus PRAVACHOL.
LIVALO vs PRAVACHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased LDL receptor expression and reduced plasma LDL-C levels.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
1-4 mg orally once daily at any time of day with or without food.
10-80 mg orally once daily, with or without food, typically in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8-14 hours), supporting once-daily dosing; no significant accumulation with repeated administration.
The terminal elimination half-life of pravastatin is approximately 1.8 hours, but clinical LDL-cholesterol lowering effects persist beyond this due to sustained HMG-CoA reductase inhibition.
Primarily biliary/fecal (approximately 90% of absorbed dose excreted in feces as parent drug and metabolites); renal excretion accounts for <5% of the dose.
Approximately 70% of an oral dose is excreted in feces, primarily as metabolites, with about 20% recovered in urine. Biliary excretion is a major route for parent drug and metabolites.
Category C
Category C
HMG-CoA Reductase Inhibitor
HMG-CoA Reductase Inhibitor